293 related articles for article (PubMed ID: 28403784)
1. Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
Devegowda PS; Balaji KS; Prasanna DS; Swaroop TR; Kameshwar VH; Jayarama S; Siddalingaiah L; Rangappa KS
Anticancer Agents Med Chem; 2018 Feb; 17(14):1931-1941. PubMed ID: 28403784
[TBL] [Abstract][Full Text] [Related]
2. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
3. Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity.
Pathak P; Shukla PK; Kumar V; Kumar A; Verma A
Inflammopharmacology; 2018 Dec; 26(6):1441-1453. PubMed ID: 29663100
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
7. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative and Antiangiogenic Properties of New VEGFR-2-targeting 2-thioxobenzo[
Abuelizz HA; Marzouk M; Bakheit AH; Awad HM; Soltan MM; Naglah AM; Al-Salahi R
Molecules; 2020 Dec; 25(24):. PubMed ID: 33333992
[TBL] [Abstract][Full Text] [Related]
9. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice.
Fan H; Wei D; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Xu Y; Hu L
Eur J Med Chem; 2019 Aug; 175():349-356. PubMed ID: 31096155
[TBL] [Abstract][Full Text] [Related]
11. Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis.
Upadhyay N; Tilekar K; Safuan S; Kumar AP; Schweipert M; Meyer-Almes FJ; Ramaa CS
Bioorg Chem; 2021 Nov; 116():105350. PubMed ID: 34547645
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
13. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
[TBL] [Abstract][Full Text] [Related]
14. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
17. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J
Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382
[TBL] [Abstract][Full Text] [Related]
18. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
[TBL] [Abstract][Full Text] [Related]
19. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.
Choudhary S; Doshi A; Luckett-Chastain L; Ihnat M; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2021 Apr; 35():116061. PubMed ID: 33647840
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]